

Accepted Manuscript

Title: Efficacy of a single oral administration of milbemycin oxime against natural infections of *Ancylostoma braziliense* in dogs

Authors: Stephen E. Bienhoff, Dawie J. Kok, Linda M. Roycroft, Elizabeth S. Roberts



PII: S0304-4017(13)00029-0
DOI: doi:10.1016/j.vetpar.2013.01.004
Reference: VETPAR 6672

To appear in: *Veterinary Parasitology*

Received date: 23-1-2012
Revised date: 2-1-2013
Accepted date: 10-1-2013

Please cite this article as: Bienhoff, S.E., Kok, D.J., Roycroft, L.M., Roberts, E.S., Efficacy of a single oral administration of milbemycin oxime against natural infections of *Ancylostoma braziliense* in dogs, *Veterinary Parasitology* (2010), doi:10.1016/j.vetpar.2013.01.004

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Title**

2 Efficacy of a single oral administration of milbemycin oxime against natural infections of

3 *Ancylostoma braziliense* in dogs

4 **Names of Authors**

5 Stephen E. Bienhoff^{a,*}, Dawie J. Kok^b, Linda M. Roycroft^a, Elizabeth S. Roberts^a

6 **Complete postal addresses of affiliations**

7 ^a Novartis Animal Health US, Inc., 3200 Northline Ave, Suite 300, Greensboro, NC 27408, USA

8 ^b ClinVet International, PO Box 11186, Universitas, Bloemfontein 9321, South Africa

9 *Corresponding author. Tel.: 336-387-1063; fax: 336-387-1459.

10 *E-mail address:* stephen.bienhoff@novartis.com (S.E. Bienhoff).

11

11 Abstract

12 The objective of this randomized, blinded, placebo controlled laboratory study was to
13 confirm the efficacy of a single oral administration of two marketed formulations of milbemycin
14 oxime (Interceptor[®] Flavor Tabs[®] and Sentinel[®] Flavor Tabs[®]) at a minimum dose of 0.5 mg/kg
15 (0.23 mg/lb) against natural infections of *Ancylostoma braziliense* in dogs. Thirty-six hookworm
16 infected dogs, a minimum of 10 weeks of age and of various breeds and genders were used.
17 Fecal egg counts were done on three separate days prior to treatment for randomization purposes.
18 Dogs were ranked by descending order of the fecal egg count arithmetic means and randomly
19 assigned to either the two milbemycin treatment groups or the placebo control group in blocks of
20 three dogs each, 12 dogs per group. Dogs were dosed according to the product label with
21 blinding maintained by separation of function. Worm counts were done at necropsy 7 days after
22 treatment. Reduction in *A. braziliense* worm counts in the milbemycin groups were compared to
23 the placebo control group using analysis of variance of the *A. braziliense* logarithmic mean
24 worm counts and percent efficacy was based on geometric means. Efficacy was defined as the
25 ability of the test products to significantly ($p \leq 0.05$) reduce parasite load by 90% or greater in
26 treated dogs when compared to adequately infected placebo control dogs. The placebo control
27 group had a geometric mean worm count of 19.2. The Interceptor treated group had a geometric
28 mean worm count of 0.38 representing a 98% reduction in parasite load and the Sentinel treated
29 group had a geometric mean worm count of 0.98 representing a 95% reduction in parasite load.
30 Both reductions were highly significant ($p < 0.0001$). In this study, milbemycin oxime, when
31 administered as two marketed formulations at a minimum dose of 0.5 mg/kg (0.23 mg/lb), was
32 efficacious for removing adult *A. braziliense* in naturally infected dogs.

33 *Keywords:* Milbemycin oxime, Interceptor[®], Sentinel[®], Natural infection, *Ancylostoma*

34 *braziliense*, Dogs

35

Accepted Manuscript

35 1. Introduction

36 *Ancylostoma braziliense* is a pathogenic hookworm parasite of dogs most generally
37 associated with warm and moist climates. Although not as pathogenic as *A. caninum*, heavy
38 infections in young dogs may result in blood loss (Rep, 1980) and hypoproteinemia (Miller,
39 1968). However, the most significant concern with *A. braziliense* is its ability to cause cutaneous
40 larva migrans in both dogs (Vetter and Leegwater-vd Linden, 1977; Vetter and van der Linden,
41 1977a; Vetter and van der Linden, 1977b; Bowman et al., 2010) and humans (Brenner and Patel,
42 2003; Patel et al., 2008; Purdy et al., 2011). Of the hookworm larvae, *A. braziliense* tends to be
43 more invasive by cutaneous penetration and shows the greatest enzyme activity for breaking
44 down structures of the skin (Hotez et al., 1992), thus allowing the larvae to enter by direct
45 contact with intact skin and mucous membranes. Not only has *A. braziliense* been associated
46 with cutaneous larva migrans in humans, but also migration to the lungs (Butland and Coulson,
47 1985) and oral mucosa (Damante et al., 2011). Even though the parasite is more common in the
48 tropical regions of the world, it has also been reported in non tropical settings (Herbener and
49 Borak, 1988), suggesting the need for control outside the areas typically considered endemic.
50 Therefore, effective control of *A. braziliense* in dogs is important because of its potential
51 pathogenicity in dogs and zoonotic potential for cutaneous larva migrans in humans.

52 Milbemycin oxime is a macrocyclic lactone that is efficacious against infections of *A.*
53 *caninum* (Blagburn et al., 1992; Niamatali et al., 1992), but no studies have been done
54 specifically investigating effectiveness against *A. braziliense*. We hypothesized that milbemycin
55 oxime would be over 90% efficacious when administered as a single treatment to dogs infected
56 with *A. braziliense*.

57

57 2. Materials and methods

58 The study was a randomized, blinded, placebo controlled laboratory study using naturally
59 infected dogs conducted in compliance with GCP (VICH GL9), South African animal welfare
60 regulations, as stipulated in the “National Code for Animal Use in Research, Education,
61 Diagnosis and Testing of Drugs and Related Substances in South Africa”. The protocol was
62 submitted to the ClinVet Animal Ethics Committee (CAEC), the composition of which was in
63 compliance with the National Code, for approval. In addition, the protocol was reviewed and
64 approved by the Novartis Animal Health US, Inc. Institutional Animal Care and Use Committee.

65 2.1. Animals

66 Thirty-six hookworm infected dogs (21 males and 15 females), a minimum of 10 weeks of
67 age and of any pure or mixed breed were randomly assigned to cages at the beginning of
68 acclimation. Animals were purchased from owners who were fully informed of the nature of the
69 study. Each dog was identified by a unique number on a collar tag. All purchase contracts
70 indicated each animal’s origin and procurement records traceable to each animal by
71 identification number. Individual dog pens were marked with corresponding animal
72 identification numbers. Potential infection with *A. braziliense* was assessed by fecal egg counts
73 (presence of hookworm eggs) for three consecutive days prior to inclusion in the study. A
74 sample of dogs from a specific source were acquired for necropsy purposes to confirm the
75 presence of *A. braziliense*. Other than intestinal parasitism, dogs were clinically healthy as
76 determined by a general physical examination and clinical pathology review. Dogs were
77 acclimated at least 7 days prior to treatment and were observed at least once daily up to the time
78 of treatment.

79

79 2.2. *Housing*

80 Dogs were housed individually. Room temperature was monitored and exercise was
81 conducted according to facility standard operating procedures, as appropriate. Animals were
82 acclimated at least seven days prior to treatment and were observed at least once daily up to the
83 time of treatment and then twice daily until euthanasia. A commercially available high quality
84 complete canine diet which provided the nutritional requirements for the age of dog used in this
85 study was offered *ad libitum* to each dog. Water was also available *ad libitum*.

86 2.3. *Randomization*

87 Fecal egg counts were done using the McMaster technique (Henriksen and Aagaard, 1976)
88 on three separate days prior to treatment for randomization purposes. Dogs were ranked by
89 descending order of the fecal egg count arithmetic means and randomly assigned to treatment in
90 blocks of three dogs each (one dog to each treatment group), 12 dogs per group.
91 Randomizations were performed in two replicates (phases), with each replicate group containing
92 18 dogs. The randomization process was applied independently within each replicate. Counts
93 were recorded as hookworm eggs per gram of feces (epg) with subsequent determination of
94 arithmetic means by a statistician.

95 2.4. *Blinding*

96 Blinding was accomplished by separation of function. Individuals responsible for general
97 health observations, clinical observations, or examination of dogs at necropsy for adult
98 *A. braziliense* worms did not know the allocation of dogs to treatment. Only the statistician and
99 individuals responsible for drug administration were aware of treatment assignments until
100 analyses.

101

101 2.5. *Procedures*

102 All dogs were fasted overnight before the day of treatment to encourage food intake prior
103 to dosing and treatment was administered within approximately 30 min after feeding. Dogs
104 received either a single oral administration of the marketed formulations of milbemycin oxime
105 (Interceptor[®] Flavor Tabs[®] or Sentinel[®] Flavor Tabs[®]; Novartis Animal Health US, Inc.)
106 according to the label at a minimum dose of 0.5 mg/kg (0.23 mg/lb) or a placebo (Pet-Tabs[®];
107 Virbac Animal Health, Inc.). Observations for adverse clinical signs were done on each dog
108 within 1 h (\pm 15 min) prior to treatment and again at 1, 4, 8 h (\pm 15 min) and 24 h (\pm 1 h) after
109 treatment. Seven days after treatment each dog was administered a lethal intravenous dose of
110 euthanasia solution (Euthapent[®]; Kyron Laboratories [Pty] Ltd) in the same order as treatment
111 group assignment for assessing adult worm counts in the intestinal tract. The dose of euthanasia
112 solution was based on the body weight determined on the day of euthanasia. Dogs were fasted
113 12 h immediately prior to euthanasia in order to decrease the amount of material in the intestinal
114 tract. The abdominal cavity was opened along the ventral midline and double ligatures were
115 placed at the cardia of the stomach and at the distal rectum prior to removal of the
116 gastrointestinal tract from the abdominal cavity. The stomach was opened along the greater
117 curvature and the contents collected in a suitable container. The mucosa was thoroughly
118 scrubbed, rinsed with water and the washings combined with the gastric contents. The mucosa
119 was inspected and any attached parasites were removed and preserved in 10% formalin or other
120 suitable preservative. In a similar manner, the small and large intestines were opened along their
121 entire length and the contents and mucosa were collected, thoroughly rinsed with water and the
122 scrapings/washings from the mucosa were combined. The mucosa was inspected and any
123 attached parasites were removed and preserved in 10% formalin. The gastric and intestinal

124 contents and rinsing fluids were washed over appropriately sized sieve(s) and any material that
125 retained in the sieve(s) was preserved in 10% formalin.

126 2.6. *Ancylostoma braziliense* identification

127 Worm recovery and identification was performed by appropriately trained and experienced
128 individuals. Prior to examining the preserved worms and washings, formalin was removed by
129 sedimentation and/or washing. Recovered worms were examined microscopically, identified to
130 genus and species based on characteristics of the buccal plates. The number of adult *A.*
131 *braziliense* recovered from each dog was recorded along with the number of other adult worms
132 recovered from each dog.

133 2.7. Statistical analyses

134 Twelve dogs were randomized to each group to increase the probability of having at least
135 six dogs adequately infected in the placebo control group indicating an adequate test. The
136 individual dog was the experimental unit. Efficacy was determined on the basis of the percent
137 reduction in adult worm counts in the treated groups compared to the placebo control group.
138 Arithmetic and geometric means of all *A. braziliense* counts were calculated.

139 Percent effectiveness was calculated using the following formula:

$$140 \quad \text{Percent Effectiveness} = 100 * ((c_c - c_t) / c_c)$$

141 where: c_c = geometric mean number of adult *A. braziliense* in the control group and c_t =
142 geometric mean number of adult *A. braziliense* in the treatment group. There were separate
143 calculations for each treatment group. Since the calculation of the geometric mean involved
144 taking the logarithm of the *A. braziliense* count of each animal, a “1” was added to the *A.*
145 *braziliense* count for every animal in every group since there were *A. braziliense* counts equal to
146 zero. This constant (1) was subtracted from the resultant calculated geometric mean prior to

147 calculating percent effectiveness. Percent effectiveness based on $\geq 90\%$ reduction in *A.*
148 *braziliense* worm burden was calculated using geometric means. All analyses were performed
149 on logarithmic means using SAS/STAT[®] software (Version 9 of the SAS System for Windows,
150 SAS Institute Inc.) and all hypotheses were tested at a two-sided 0.05 level of significance.

151

152 3. Results

153 Of the 36 dogs enrolled in the study, 21 were male and 15 were female (Placebo = 5 males
154 and 7 females; Interceptor = 8 males and 4 females; Sentinel = 8 males and 4 females). Dogs
155 treated with Interceptor or Sentinel received a mean milbemycin oxime dose of 0.57 ± 0.08 and
156 0.57 ± 0.05 mg/kg, respectively. All dogs were reported as being over 10 months of age and the
157 weight ranged from 10.3 to 46.8 kg two days prior to dosing (weight used to determine dose).
158 There were no significant differences in body weights between treatment groups. Breeds
159 represented were variable and included purebred and mixed Alsatians (German Shepherds),
160 South African Boerboels, Border Collies, Chihuahuas, Dachshunds, Dobermans, Greyhounds,
161 Labradors, Maltese, Ridgebacks, Rottweilers and Terriers. Adult worms other than *A.*
162 *braziliense* that were identified during necropsy included *Ancylostoma caninum*, *Uncinaria*
163 *stenocephala*, *Trichuris vulpis*, *Toxocara canis*, *Toxascaris leonina*, *Dipylidium caninum*, *Taenia*
164 spp. and *Echinococcus granulosus*. Efficacy against these parasites was consistent with label
165 indications.

166 Of the 12 dogs in the placebo control group, seven had more than 20 *A. braziliense* isolated
167 at necropsy and 10 had more than five isolated at necropsy (range 10 to 100) indicating the
168 presence of an adequate infection in the study dogs. Statistically, both milbemycin treatment
169 groups had significantly ($p < 0.0001$) fewer *A. braziliense* isolated at necropsy when compared to

170 the placebo control group. All surviving *A. braziliense* were isolated from the small intestines.
171 The calculated efficacy based on geometric means was 98% for the Interceptor[®] group and 95%
172 for the Sentinel[®] group (**Table 1**). Despite careful and frequent observations of the study
173 animals, no adverse events, abnormal clinical observations, or abnormal health observations
174 were observed during the study. In addition, there were no statistically significant differences in
175 body weight change between groups.
176

176 4. Discussion

177 Macrocytic lactones have excellent antihelmintic activity and have been shown to be
178 effective against hookworm infections in dogs and cats (Anderson and Roberson, 1982;
179 Blagburn et al., 1992; Niamatali et al., 1992; Nolan et al., 1992; Six et al., 2000). Milbemycin
180 oxime is a macrocytic lactone that is efficacious against infections of *A. caninum* (Blagburn et
181 al., 1992; Niamatali et al., 1992), but no studies have been done specifically investigating
182 effectiveness against *A. braziliense*, as has been done for other compounds (Robinson et al.,
183 1976; Anderson and Roberson, 1982). In this study, we specifically investigated the
184 effectiveness of a single oral administration of milbemycin oxime in two commercial
185 formulations (Interceptor[®] Flavor Tabs[®] and Sentinel[®] Flavor Tabs[®]) at a minimum dose of 0.23
186 mg/lb (0.5 mg/kg) against natural infections of *A. braziliense* in dogs. We hypothesized that
187 milbemycin oxime would be over 90% efficacious when administered as a single treatment.
188 Naturally infected dogs from South Africa were used as *A. braziliense* is known to be endemic to
189 this area (Verster, 1979; Minnaar and Krecek, 2001; Minnaar et al., 2002).

190 The study design was based on the known life-cycle of *A. braziliense* and is routinely used
191 to determine the efficacy of anthelmintics in well controlled laboratory settings. Thirty-six
192 clinically healthy dogs (other than intestinal parasitism) of various breeds and body weights that
193 were a minimum of 10 weeks of age were used and were representative of the general dog
194 population present in South Africa. Statistically, both of the milbemycin oxime treatment groups
195 had significantly ($p < 0.0001$) fewer *A. braziliense* isolated at necropsy when compared to the
196 placebo control group with reductions ranging from 94.91% (Sentinel) to 98.02% (Interceptor)
197 from a single administration. Taken together, these results confirm that all requirements for an
198 adequate test of efficacy were met in this study.

199 No adverse events were reported nor were there any significant reductions in body weight
200 observed indicating milbemycin oxime in these formulations was well tolerated, which is
201 consistent with previous studies that have shown milbemycin oxime is safe when administered
202 orally for control of nematode parasites (Ide et al, 1993).

203

204 **5. Conclusion**

205 This study demonstrates milbemycin oxime, when administered in the commercial
206 formulations of Interceptor[®] Flavor Tabs[®] and Sentinel[®] Flavor Tabs[®] at a minimum
207 milbemycin oxime dose of 0.5 mg/kg (0.23 mg/lb), is efficacious for the removal and control of
208 adult *A. braziliense* in dogs.

209

210 **Acknowledgements**

211 The authors thank Dr. Barry Hyman for his oversight during the conduct of the study.

212

213 **Conflict of interest**

214 The study was funding by Novartis Animal Health Inc. Global Technical Services.
215 Logistics and technical support, including the design of the study, statistical analyses,
216 interpretation of results and writing the manuscript was done by Novartis Animal Health US, Inc.
217 New Product Development. Three of the authors are employees of Novartis Animal Health US,
218 Inc. who manufactures Interceptor[®] Flavor Tabs[®] and Sentinel[®] Flavor Tabs[®]. Dawie Kok was
219 contracted by Novartis Animal Health US, Inc. to conduct the study.

220

221

221 **References**

- 222 Anderson, D.L., Roberson, E.L., 1982. Activity of ivermectin against canine intestinal
223 helminths. *Am. J. Vet. Res.* 43, 1681-1683.
224
- 225 Blagburn, B.L., Hendrix, C.M., Lindsay, D.S., Vaughan, J.L., Hepler, D.I., Wright, J.C., 1992.
226 Efficacy of milbemycin oxime against naturally acquired or experimentally induced *Ancylostoma*
227 spp. and *Trichuris vulpis* infections in dogs. *Am. J. Vet. Res.* 53, 513-516.
228
- 229 Bowman, D.D., Montgomery, S.P., Zajac, A.M., Eberhard, M.L., Kazacos, K.R., 2010.
230 Hookworms of dogs and cats as agents of cutaneous larva migrans. *Trends Parasitol.* 26, 162-
231 167.
232
- 233 Brenner, M.A., Patel, M.B., 2003. Cutaneous larva migrans: the creeping eruption. *Cutis* 72,
234 111-115.
235
- 236 Butland, R.J.A., Coulson, I.H., 1985. Pulmonary eosinophilia associated with cutaneous larva
237 migrans. *Thorax* 40, 76-77.
238
- 239 Damante, J.H., Chinellato, L.E.M., de Oliveira, F.T., Soares, C.T., Fleury, R.N., 2011. *Larva*
240 *migrans* in the oral mucosa: report of two cases. *Braz. Dent. J.* 22, 166-170.
241
- 242 Henriksen, S.A., Aagaard, K.A., 1976. A simple flotation and McMaster method. *Nord. Vet.*
243 *Med.* 28, 392-397.

244

245 Herbener, D., Borak, J., 1988. Cutaneous larva migrans in northern climates. *Am. J. Emerg.*

246 *Med.* 6, 262-264.

247

248 Hotez, P.J., Narasimhan, S., Haggerty, J., Milstone, L., Bhopale, V., Schad, G.A., Richards, F.F.,

249 1992. Hyaluronidase from infective *Ancylostoma* hookworm larvae and its possible function as a

250 virulence factor in tissue invasion and in cutaneous larva migrans. *Infect. Immun.* 60, 1018-

251 1023.

252

253 Ide, J., Okazaki, T., Ono, M., Saito, A., Nakagawa, K., Naito, S., Sato, K., Tanaka, K.,

254 Yoshikawa, H., Ando, M., Katsumi, S., Matsumoto, K., Toyama, T., Shibano, M., Abe, M.,

255 1993. Milbemycin: Discovery and Development. *Annu. Rep. Sanko. Res. Lab.* 45, 1-98.

256

257 Miller, T.A., 1968. Pathogenesis and immunity in hookworm infection. *Trans. R. Soc. Trop.*

258 *Med. Hyg.* 62, 473-489.

259

260 Minnaar, W.N., Krecek, R.C., 2001. Helminths in dogs belonging to people in a resource-

261 limited urban community in Gauteng, South Africa. *Onderstepoort J. Vet. Res.* 68, 111-117.

262

263 Minnaar, W.N., Krecek, R.C., Fourie, L.J., 2002. Helminths in dogs from a peri-urban resource-

264 limited community in Free State Province, South Africa. *Vet. Parasitol.* 107, 343-349.

265

- 266 Niamatali, S., Bhopale, V., Schad, G.A., 1992. Efficacy of milbemycin oxime against
267 experimentally induced *Ancylostoma caninum* and *Uncinaria stenocephala* infections in dogs. J.
268 Am. Vet. Med. Assoc. 201, 1385-1387.
- 269
- 270 Nolan, T.J., Niamatali, S., Bhopale, V., Longhofer, S.L., Schad, G.A., 1992. Efficacy of a
271 chewable formulation of ivermectin against a mixed infection of *Ancylostoma braziliense* and
272 *Ancylostoma tubaeforme* in cats. Am. J. Vet. Res. 53, 1411-1413.
- 273
- 274 Patel, S., Aboutalebi, S., Vindhya, P.L., Smith, J., 2008. What's eating you? Extensive
275 cutaneous larva migrans (*Ancylostoma braziliense*). Cutis 82, 239-240.
- 276
- 277 Purdy, K.S., Langley, R.G., Webb, A.N., Walsh, N., Haldane, D., 2011. Cutaneous larva
278 migrans. The Lancet 377, 1948.
- 279
- 280 Rep, B.H., 1980. Pathogenicity of hookworms. The significance of population regression for
281 the pathogenicity of hookworms. Trop. Geogr. Med. 32, 251-255.
- 282
- 283 Robinson, M. Hooke, F.G., Iverson, K.E., 1976. Efficacy of pyrantel pamoate and piperazine
284 citrate against roundworm and hookworm species in dogs. Aust. Vet. Pract. 6, 104-108.
- 285
- 286 Six, R.H., Sture, G.H., Thomas, C.A., Clemence, R.G., Benchaoui, H.A., Boy, M.G., Watson, P.,
287 Smith, D.G., Jernigan, A.D., Rowan, T.G., 2000. Efficacy and safety of selamectin against
288 gastrointestinal nematodes in cats presented as veterinary patients. Vet. Parasitol. 91, 321-331.

289

290 Verster, A., 1979. Gastro-intestinal helminths of domestic dogs in the Republic of South Africa.

291 Onderstepoort J. Vet. Res., 79-82.

292

293 Vetter, J.C., Leegwater-vd Linden, M.E., 1977. Skin penetration of infective hookworm larvae.

294 III. Comparison studies on the path of migration of the hookworms *Ancylostoma braziliense*,

295 *Ancylostoma ceylanicum*, and *Ancylostoma caninum*. Z. Parasitenkd. 53, 155-158.

296

297 Vetter, J.C., van der Linden, M.E., 1977a. Skin penetration of infective hookworm larvae. I.

298 The path of migration of infective larvae of *Ancylostoma braziliense* in canine skin. Z.

299 Parasitenkd. 53, 255-262.

300

301 Vetter, J.C., van der Linden, M.E., 1977b. Skin penetration of infective hookworm larvae. II.

302 The path of migration of infective larvae of *Ancylostoma braziliense* in the metacarpal foot pads

303 of dogs. Z. Parasitenkd. 53, 263-266.

304

304 **Tables**

305 **Table 1.** *Ancylostoma braziliense* geometric mean counts, percent efficacy and statistical
 306 significance by treatment group.

Treatment Group	Geometric mean	Arithmetic mean	% Efficacy†	p-value
Placebo Control	19.227	35.500	NA	NA
Interceptor® Flavor Tabs®	0.381	0.583	98.02	<0.0001*
Sentinel® Flavor Tabs®	0.979	2.167	94.91	<0.0001*

307 * Statistically significant at $p \leq 0.05$ when geometric means were compared to Placebo

308 † Percent efficacy based on geometric means

309